Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
si-CDKN2B-AS1
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
si-CDKN2B-AS1 is a small interfering RNA (siRNA) designed to silence the long non-coding RNA (lncRNA) CDKN2B-AS1 (cyclin-dependent kinase inhibitor 2B antisense RNA 1). In pathological conditions such as childhood asthma, CDKN2B-AS1 is upregulated and recruits DNA methyltransferase 1 (DNMT1) to the promoter of ZFP36, leading to its methylation and subsequent downregulation. By silencing CDKN2B-AS1, this siRNA restores ZFP36 expression, which then interacts with NR4A1 to inhibit the NF-κB signaling pathway. This therapeutic approach aims to reduce airway inflammation, inhibit apoptosis of bronchial epithelial cells, and alleviate airway hyperresponsiveness.
- Other names
- CDKN2B-AS1 siRNACDKN-2B-AS1 siRNACDKN 2B-AS1 siRNAsmall interfering RNA against CDKN2B-AS1
02
Targets
CDKN2B-AS1 (CDKN2B antisense RNA 1)
Beyond the preview
Go deeper on si-CDKN2B-AS1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on si-CDKN2B-AS1.